Back to News
Market Impact: 0.25
NeuroSense Therapeutics Consensus Price Target Increased by 1,507.27% to $112.71
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
NeuroSense Therapeutics' average one-year analyst price target was revised to $112.71 per share from $7.01 on September 11, 2026, a 1,507.27% increase. The update reflects aggregated analyst targets and signals substantially more bullish valuation expectations, though the article provides no underlying estimate count, ratings, or operating catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
NRSN0.75
More News
- NeuroSense Provides Update on Nasdaq Listing Compliance
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Tesla reports 486,532 vehicle deliveries for third quarter, topping expectation
- Rivian tops Q3 delivery expectations, reconfirms 2026 guidance